HONG KONG--(BUSINESS WIRE)--Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau. The testing services will be performed by the Inocras laboratory in San Diego, which holds CLIA-certified, CAP-accredited to provide the highest quality and reliability of test results.
How the Program Works:
Eligible patients in both the private and public sectors can apply for the free genetic tests through their physicians. The program will offer BRCA or HRD testing to eligible patients diagnosed with breast cancer and ovarian cancer, prostate cancer and pancreatic cancer. Eligible patients are also entitled to free pre-test or post-test genetic counselling session. With this program, individuals diagnosed with cancer can gain access to advanced genetic testing-informed treatment planning and personalized care.
"We are proud to leverage our cutting-edge technology and expertise to offer free genetic testing services to eligible cancer patients in Hong Kong and Macau," said Stephanie Sunkyung Yang, CEO of Inocras Hong Kong Limited. "Our collaboration with Cancerinformation.com.hk Charity Foundation and sponsorship from AstraZeneca Hong Kong highlights our commitment to advancing precision medicine and providing personalized care to individuals battling cancer."
“We are delighted to be part of this collaborative effort with Inocras Hong Kong Limited, along with the generous support from AstraZeneca Hong Kong. Through this joint initiative with Inocras, we aim to make a significant difference in the lives of cancer patients and their families by providing crucial support throughout their treatment journey,” said Natalie Fong, Chairman of Cancerinformation.com.hk Charity Foundation. “Our collective mission is to promote the importance of early detection within the community, ultimately improving patients’ overall health outcomes.”
The partnership between Inocras, CICF, and AstraZeneca Hong Kong signifies a significant step forward in making advanced genetic testing and precision medicine accessible to cancer patients in the region. By leveraging Inocras's innovative testing services and comprehensive genetic analyses, patients can make informed treatment decisions and may see potential benefits in their overall health outcomes.
About Inocras Hong Kong Limited:
Inocras Hong Kong Limited, as a subsidiary of Inocras Inc. with its headquarter in San Diego, the USA(formerly Genome Insight, Inc), is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases. The company is dedicated to unlocking the potential of genomic data to enable precision health for everyone. To learn more, visit Inocras.com.
About Cancerinformation.com.hk Charity Foundation:
Cancerinformation.com.hk Charity Foundation (CICF) is a local NGO dedicated to supporting cancer patients and their caregivers in Hong Kong. With a comprehensive approach, our services encompass financial aid, psychological counselling, rehabilitation, and community support programs. Through different public education initiatives, we strive to promote early detection and improved access to cancer care and resources within the community. To learn more, visit https://cicf.org.hk/.
